Mayesta

Isotretinoin, the active ingredient in Mayesta, is a retinoid presented as an oral formulation for oral use. It is indicated for the treatment of severe recalcitrant nodular acne in patients who have not responded to conventional therapies.

GNH USA supplies Mayesta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mayesta (isotretinoin) belongs to the retinoid class and is used to treat severe forms of acne vulgaris.

Severe nodular acne: reduces inflammatory lesions and prevents new nodule formation. Acne conglobata: helps clear extensive, deep‑seated lesions. Recalcitrant acne: provides therapeutic benefit when other systemic treatments have failed.

Isotretinoin is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dry skin and mucous membranes. - Cheilitis (cracked lips). - Xerosis (dry eyes). - Increased photosensitivity. - Headache. - Myalgia.

Serious or Rare Side Effects: - Severe depression or suicidal ideation. - Inflammatory bowel disease. - Elevated liver enzymes. - Hypertriglyceridemia. - Pseudotumor cerebri. - Teratogenicity (birth defects).

Isotretinoin requires careful monitoring and adherence to safety guidelines. - Pregnancy: contraindicated; ensure effective contraception before, during, and after therapy. - Laboratory monitoring: baseline and periodic liver function tests and lipid profiles. - Vitamin A supplementation: avoid concurrent use to prevent additive toxicity. - Sun exposure: limit and use broad‑spectrum sunscreen. - Psychiatric symptoms: monitor for depression or mood changes. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Isotretinoin may interact with several medications, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Tetracyclines: risk of intracranial hypertension. - Vitamin A supplements: additive teratogenic and toxicity risk. - Systemic corticosteroids: may diminish isotretinoin effectiveness.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in contraceptive reliability. - Anticoagulants (e.g., warfarin): monitor INR for changes. - Lamotrigine: increased risk of severe skin reactions.